APP and Alzheimer disease: After treatment with 5 μM GSK‐650394 in AD model N2a‐APP cells for 48 h, it was found that the p‐FOXO3a/total FOXO3a ratio decreased significantly compared with the DMSO‐treated control group (Figure S8B), suggesting that there may be changes in APP metabolism.